Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Belite Bio, Inc. Sponsored ADR (BLTE) vs Ligand Pharmaceuticals Incorporated (LGND)

Belite Bio, Inc. Sponsored ADR and Ligand Pharmaceuticals Incorporated are both Biotechnology companies. Belite Bio, Inc. Sponsored ADR is the larger, with a market value of $6.8B against $6.1B — 1.1× the size. Belite Bio, Inc. Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Ligand Pharmaceuticals Incorporated trades at 30.1×. Ligand Pharmaceuticals Incorporated has the higher net margin (67.9% vs 0.00%) and the higher return on invested capital (8.19% vs −9.55%). Across the 13 metrics below, Ligand Pharmaceuticals Incorporated leads on 11 and Belite Bio, Inc. Sponsored ADR on 2.

Valuation

Metric BLTE LGND Biotechnology median
P/E n/m 30.12 7.88
P/S n/m 20.82 11.47
P/B 8.73 6.25 2.52
Price to free cash flow n/m 42.20 21.16
EV/EBITDA n/m 46.73 0.74
EV/Sales n/m 19.98 10.73
Earnings yield (1.63%) 3.32% (28.84%)
Free cash flow yield (0.99%) 2.37% (23.03%)

Profitability

Metric BLTE LGND Biotechnology median
Gross margin — 95.43% 65.16%
Operating margin 0.00% 32.61% 0.00%
Net margin 0.00% 67.88% 0.00%
Free cash flow margin 0.00% 49.34% 0.00%
Return on equity 0.00% 21.96% (57.72%)
Return on assets (21.60%) 12.58% (49.22%)
Return on invested capital (9.55%) 8.19% 0.00%

Growth

Metric BLTE LGND Biotechnology median
Revenue growth (TTM) — 54.89% 5.64%
EPS growth (last fiscal year) (95.76%) 2,886.36% —
Revenue growth, 5-year CAGR — 10.39% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLTE LGND Biotechnology median
Debt to equity 0.00 1.16 0.00
Current ratio 33.56 31.18 4.73
Net debt to EBITDA 5.88 (4.36) 0.96

Dividend

Metric BLTE LGND Biotechnology median
Dividend yield — 2.04% 2.10%
Payout ratio — 0.00 0.00

Size

Metric BLTE LGND Biotechnology median
Market cap 6.82b 6.09b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack